Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
44 hedge funds and large institutions have $160M invested in Alpine Immune Sciences Inc in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
46% more capital invested
Capital invested by funds: $110M → $160M (+$50.5M)
26% more funds holding
Funds holding: 35 → 44 (+9)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.3M |
| 2 |
Morgan Stanley
New York
|
+$3.68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.26M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$1.45M |
| 5 |
PVI
Pura Vida Investments
New York
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.89M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.31M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$932K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$344K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$131K |
ALPN Hedge Fund Activity: Q4 2020 in Review
44 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2020, worth a combined $160M — up 46% from $110M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ALPN positions and 2 closed out — a net gain of 9 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $4.3M. The largest seller was OrbiMed, cutting an estimated $5.89M.
- 44 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2020, up from 35 in Q3 2020.
- Funds reported $160M of Alpine Immune Sciences Inc stock for Q4 2020, up 46% quarter-over-quarter.
- 11 funds opened new Alpine Immune Sciences Inc positions in Q4 2020 and 2 closed out, a net change of +9 holders.
- The largest Alpine Immune Sciences Inc buyer in Q4 2020 was Avidity Partners Management, an estimated $4.3M added.
- The largest Alpine Immune Sciences Inc seller in Q4 2020 was OrbiMed, an estimated $5.89M sold.
Based on aggregated 13F filings for Q4 2020.